CS Medica Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

CS Medica şirketinin toplam hissedar öz sermayesi DKK1.8M ve toplam borcu DKK12.3M olup, bu da borç-öz sermaye oranını 676.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla DKK34.2M ve DKK32.3M dir.

Anahtar bilgiler

676.5%

Borç/özkaynak oranı

DKK 12.30m

Borç

Faiz karşılama oranı	n/a
Nakit	DKK 51.95k
Eşitlik	DKK 1.82m
Toplam yükümlülükler	DKK 32.35m
Toplam varlıklar	DKK 34.17m

Son finansal sağlık güncellemeleri

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Jun 04

Recent updates

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Jun 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CSMED 'nin kısa vadeli varlıkları ( DKK4.9M ) kısa vadeli yükümlülüklerini ( DKK18.4M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: CSMED 'un kısa vadeli varlıkları ( DKK4.9M ) uzun vadeli yükümlülüklerini ( DKK13.9M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CSMED 'nin net borç/öz sermaye oranı ( 673.6% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: CSMED şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CSMED şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CSMED un, serbest nakit akışı her yıl % 13.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

CS Medica Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Recent updates

New minor risk - Shareholder dilution

New major risk - Market cap size

CS Medica A/S Announces Approval of CANNASEN Pain Patch in Malaysia and Trademark Registration in Thailand

Third quarter 2024 earnings released

CS MEDIC Receives "Intention to Grant" for European Patent Application Concerning Cannasen® Psoriasis Gel, Reinforcing Leadership in Cbd-Infused Dermatological Innovations

CS Medica A/S to Report Q3, 2024 Results on Jul 31, 2024

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Second quarter 2024 earnings released

CS Medica A/S to Report Fiscal Year 2024 Results on Nov 28, 2024

CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia

CS Medica A/S to Report 3 Months Period Ending Dec 31, 2023 Results on Mar 29, 2024

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report 3 Months 2023 Final Results on Apr 24, 2024

CS Medica A/S Announces FDA Authorization for Commercialization for Eight Products in the U.S. Market

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report Q4, 2024 Results on Nov 14, 2024

Cs Medica A/S Announces Indian State's Fda Approval for Two Cosmetic Products

New major risk - Share price stability

New major risk - Market cap size

CS Medica A/S to Report Q3, 2023 Results on Aug 08, 2023

CS Medica A/S to Report Q3, 2023 Results on Jul 18, 2023

CS Medica A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body

New major risk - Market cap size

CS Medica A/S Announces Positive Results from Clinical Trial of Nasal Protect Gel for Hay Fever/Allergic Rhinitis

CS Medica A/S to Report Fiscal Year 2022 Final Results on Jan 27, 2023

CS Medica A/S to Report Q1, 2023 Results on Feb 17, 2023

CS Medica A/S, Annual General Meeting, Feb 09, 2023

CS Medica A/S Provides Update on Clinical Trials

Full year 2022 earnings released: kr.0.90 loss per share (vs kr.0.059 profit in FY 2021)

No independent directors

CS Medica A/S and CanNordic A/S Announce the Resignation of Bo Unéus as Board Member

CS Medica A/S Provides Revenue Guidance for the Year 2022

CS MEDICA Provides Patent Update

CS Medica A/S to Report Fiscal Year 2022 Results on Nov 18, 2022

CS MEDICA A/S Reports Proof of Concept in the Results from the Clinical Trial on NGP-01 (Cannasen®Cbd Psoriasis Gel) Against Placebo

CS MEDICA A/S Announces Groundbreaking Discovery in the Natural Cannabinoid CBD's Activity in the Body

Cs Medica Announces Positive Clinical Trial Results from the Final Report on Nga-01 Gel & Nsa-01 Capsule in Combination Against Placebo

CS Medica A/S Reports the Results from the Clinical Trial on NGA-01(CANNASEN®CBD Arthritis Gel) Against Placebo

CS MEDICA A/S Provides Revenue Guidance for 2023/2024

No independent directors

CS Medica Receives the Final Approval from Hong Kong Customs, the Drug Registration Office

CS MEDICA A/S Provides Patent Update

CS MEDICA A/S Finalizes THC Test At PPB Level on Their Cannasen®Cbd Products to Comply with the Strict Regulations on the Asian Market

CS MEDICA A/S Appoints Heidi Ahlefeldt-Laurvig as Chief Growth Officer and Chief Marketing Officer, Effective May 1, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

CS MEDICA A/S Reaffirms Revenue Guidance for the Fiscal Year 2022

CS MEDICA A/S Announces Their CANNANSEN®CBD Anti-Hair Loss Serum Approves in the United Arab Emirates

CS MEDICA A/S Announces an Additional Five Intellectual Property Rights Registrations

No independent directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin